|
End-of-day quote
Nasdaq
|
||
| - USD | - |
|
| 11-19 | B. Riley Trims Microbot Medical Price Target to $3 From $4, Maintains Buy Rating | MT |
| 11-16 | Top Premarket Decliners | MT |
| Market Cap | 49.92M 45.53M 41.91M 38.15M 71.59M 4.63B 75.47M 510M 203M 2.52B 187M 183M 7.91B | P/E 2026 * |
-2.15x | P/E 2027 * | -1.99x |
|---|---|---|---|---|---|
| Enterprise Value | 49.92M 45.53M 41.91M 38.15M 71.59M 4.63B 75.47M 510M 203M 2.52B 187M 183M 7.91B | EV / Sales 2026 * |
71.3x | EV / Sales 2027 * | 13.1x |
| Free-Float |
100% | Yield 2026 * |
-
| Yield 2027 * | - |
Last Transcript: StemCells Inc
| Manager | Title | Age | Since |
|---|---|---|---|
Harel Gadot
CEO | Chief Executive Officer | 54 | 02/08/1988 |
Rachel Vaknin
DFI | Director of Finance/CFO | 48 | 01/04/2022 |
Michal Ahuvia
COO | Chief Operating Officer | - | 21/01/2025 |
| Director | Title | Age | Since |
|---|---|---|---|
Harel Gadot
CHM | Chairman | 54 | 01/01/2013 |
Scott Burell
BRD | Director/Board Member | 61 | 28/11/2016 |
Martin Madden
BRD | Director/Board Member | 66 | 06/02/2017 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
| -2.49% | -6.35% | +51.07% | +64.95% | 65.42B | ||
| -0.63% | -3.81% | +6.95% | +88.55% | 58.91B | ||
| -2.37% | -2.22% | +22.96% | +83.44% | 55.24B | ||
| -2.19% | -6.02% | +10.50% | +109.19% | 45.66B | ||
| -1.89% | -9.33% | +13.03% | +20.04% | 41.29B | ||
| -0.93% | +1.67% | +20.83% | +45.03% | 36.82B | ||
| +1.11% | -8.59% | +128.56% | +655.74% | 34.48B | ||
| -0.80% | -1.73% | +75.29% | +56.47% | 32.5B | ||
| -2.17% | +19.70% | -30.57% | +469.42% | 31.69B | ||
| Average | -1.37% | -0.66% | +33.18% | +176.98% | 45B | |
| Weighted average by Cap. | -1.49% | -1.28% | +31.63% | +151.41% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 700K 638K 588K 535K 1M 64.86M 1.06M 7.16M 2.84M 35.36M 2.63M 2.57M 111M | 3.81M 3.48M 3.2M 2.91M 5.47M 353M 5.76M 38.98M 15.48M 193M 14.3M 14M 604M |
| Net income | -21.47M -19.58M -18.02M -16.4M -30.78M -1.99B -32.45M -219M -87.17M -1.08B -80.53M -78.84M -3.4B | -24.59M -22.43M -20.65M -18.79M -35.26M -2.28B -37.17M -251M -99.85M -1.24B -92.25M -90.31M -3.9B |
| Net Debt | - | - |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Select your edition
All financial news and data tailored to specific country editions
















